Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial

Hospitalized patients with COVID-19 are at increased risk of thrombosis, acute respiratory distress syndrome and death. The optimal dosage of thromboprophylaxis is unknown. The aim was to evaluate the efficacy and safety of tinzaparin in prophylactic, intermediate, and therapeutic doses in non-criti...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz-Rivas, Nuria, Aibar, Jesús, Gabara-Xancó, Cristina, Trueba-Vicente, Ángela, Urbelz-Pérez, Ana, Gómez-Del Olmo, Vicente, Demelo-Rodríguez, Pablo, Rivera-Gallego, Alberto, Bosch-Nicolau, Pau, Perez-Pinar, Montserrat, Rios-Prego, Mónica, Madridano-Cobo, Olga, Ramos-Alonso, Laura, Alonso-Carrillo, Jesús, Francisco-Albelsa, Iria, Martí-Saez, Edelmira, Maestre-Peiró, Ana, Méndez-Bailón, Manuel, Hernández-Rivas, José Ángel, Torres-Macho, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571371/
https://www.ncbi.nlm.nih.gov/pubmed/36233500
http://dx.doi.org/10.3390/jcm11195632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571371/
https://www.ncbi.nlm.nih.gov/pubmed/36233500
http://dx.doi.org/10.3390/jcm11195632

Ejemplares similares